BioMed Research International

BioMed Research International / 2014 / Article
Special Issue

Recent Advances and Future Perspective in Microbiota and Probiotics

View this Special Issue

Research Article | Open Access

Volume 2014 |Article ID 393598 |

Suguru Shigemori, Kazushi Oshiro, Pengfei Wang, Yoshinari Yamamoto, Yeqin Wang, Takashi Sato, Yutaka Uyeno, Takeshi Shimosato, "Generation of Dipeptidyl Peptidase-IV-Inhibiting Peptides from β-Lactoglobulin Secreted by Lactococcus lactis", BioMed Research International, vol. 2014, Article ID 393598, 8 pages, 2014.

Generation of Dipeptidyl Peptidase-IV-Inhibiting Peptides from β-Lactoglobulin Secreted by Lactococcus lactis

Academic Editor: Julio Villena
Received02 Jul 2014
Accepted15 Jul 2014
Published03 Aug 2014


Previous studies showed that hydrolysates of β-lactoglobulin (BLG) prepared using gastrointestinal proteases strongly inhibit dipeptidyl peptidase-IV (DPP-IV) activity in vitro. In this study, we developed a BLG-secreting Lactococcus lactis strain as a delivery vehicle and in situ expression system. Interestingly, trypsin-digested recombinant BLG from L. lactis inhibited DPP-IV activity, suggesting that BLG-secreting L. lactis may be useful in the treatment of type 2 diabetes mellitus.

1. Introduction

β-Lactoglobulin (BLG) is the major whey protein in the milk of cows and other ruminants, as well as some nonruminants, but it is not contained in human breast milk [1]. BLG is widely recognized as a high-functional protein [2]. Previous studies have consistently demonstrated that hydrolysates of BLG prepared using gastrointestinal proteases such as trypsin or pepsin have an inhibitory effect on dipeptidyl peptidase-IV (DPP-IV, also known as CD26) activity [38]. DPP-IV is a serine protease that is ubiquitously expressed in vivo, and its endogenous physiological substrates are incretins [9]. The incretins, primarily glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, are gastrointestinal hormones released from intestinal L and K cells, respectively. Incretins drive insulin secretion in pancreatic β cells and suppress pancreatic glucagon production [10, 11]. Thus, DPP-IV inhibitors, such as vildagliptin, saxagliptin, sitagliptin, alogliptin, and linagliptin, are used in the management of type 2 diabetes mellitus (T2D).

We hypothesized that intestinal mucosa-targeted oral delivery of BLG might be a useful strategy for managing T2D. Generally recognized as safe (i.e., GRAS), genetically modified lactic acid bacteria (LAB) have recently emerged as vehicles for the efficient delivery of therapeutic proteins and as stable producers of these proteins in situ [12]. In this study, we engineered a Lactococcus (L.) lactis strain to secrete BLG and validated the DPP-IV-inhibiting activity of trypsin-digested recombinant BLG (rBLG).

2. Materials and Methods

2.1. Bacterial Strains and Growth Conditions

L. lactis NZ9000 (NZ9000; MoBiTec, Goettingen, Germany), derived from L. lactis subsp. cremoris MG1363 (MG1363), which harbors the regulatory genes nisR and nisK integrated into the pepN gene, was used as a host strain. NZ9000 was grown at 30°C without shaking in M17 broth (OXOID, Hampshire, UK) supplemented with 0.5% glucose (GM17). rNZ9000 strains were grown in GM17 with 20 μg/mL of chloramphenicol.

2.2. Construction of rNZ9000 Strains

To create the secretion vector for L. lactis, the sequence of usp45, the lactococcal signal peptide, was inserted into pNZ8148#2:CYT [13] between the nisin-inducible promoter () and 6x His-tag sequences; the resulting plasmid was designated pNZ8148#2:SEC (Figure 1(a)). The pNZ8148#2:CYT vector is a modified form of the L. lactis expression vector pNZ8148 (MoBiTec).

The gene encoding BLG (accession number: EU883598) was synthesized and subcloned into pGEM-T easy optimized for MG1363 codon-usage by Eurofins Genomics (Tokyo, Japan). The sequence of the BLG gene was subsequently cloned between the KpnI and HindIII restriction sites in pNZ8148#2:SEC, generating pNZ8148#2:SEC-BLG (Figure 1(b)).

The pNZ8148#2:SEC-BLG vector was introduced into NZ9000 by electroporation using a Gene Pulser Xcell electroporation system (Bio-Rad Laboratories Inc., CA, USA) following the manufacturer’s instructions. The resulting recombinant strain was designated NZ9000:SEC-BLG. NZ9000 was also electroporated with the empty plasmid pNZ8148#2:SEC to generate an NZ9000 vector control strain (NZ9000:SEC-VC).

2.3. Small-Scale Expression of rBLG

A 1.9 mL aliquot of fresh medium was inoculated with 0.1 mL of an overnight culture and incubated at 30°C without shaking. When the turbidity of the culture reached an optical density at 600 nm (OD600) of 0.4 (1.5 to 2 h later), various concentrations of nisin were added and the culture was incubated for an additional 3 to 4 h. The OD600 of the culture was measured at the end of the incubation period.

Cells were isolated from the nisin-induced culture via centrifugation for 1 min at 8,000 ×g and 4°C. Protein extracts were prepared from the cells using previously described methods [14]. Proteins remaining in the supernatant were isolated and concentrated using trichloroacetic acid (TCA) precipitation. Briefly, 300 μL of cold 100% (w/v) TCA solution was added to 1.5 mL of supernatant and the mixture was placed on ice for 3 h. The resulting precipitates were pelleted by centrifugation at 20,400 ×g and 4°C. To completely remove the TCA, the protein pellet was washed twice with ice-cold acetone. The resulting pellet was dried at 55°C and then dissolved in a small amount of TE buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA). An equal volume of 2x sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer was added to each sample. The cell and supernatant fractions were boiled for 5 min or placed at room temperature overnight, respectively, and then subjected to SDS-PAGE (15% (v/v) polyacrylamide).

Electrophoresed proteins were transferred from the gel onto a Hybond-P polyvinylidene difluoride membrane (GE Healthcare, Buckinghamshire, UK). Western blotting was performed with primary antibody (Ab) against the 6x His-tag (1:1,000; BioLegend Inc., San Diego, CA, USA), followed by incubation with a horseradish peroxidase-conjugated secondary Ab (1:5,000; Sigma, St. Louis, MO, USA). The resulting blots were visualized using an ECL Western Blotting Analysis System (GE Healthcare). Signals were detected using a lumino image analyzer (ImageQuant LAS 4000 mini, GE Healthcare) and analyzed using ImageQuant TL software (GE Healthcare).

2.4. Purification of rBLG

Expression of rBLG in NZ9000:SEC-BLG was induced in a 4 L large-scale culture according to the above-mentioned methods. Following induction of rBLG expression, cells were harvested by centrifugation for 20 min at 3,000 ×g and 4°C. The cell pellet was washed twice with phosphate buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0) and resuspended with 80 mL of phosphate buffer containing EDTA-free proteinase inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). To disrupt the cells, the bacterial suspension was homogenized with 0.2 mm glass beads for 3 min using a beads beater (Beads Crasher μT-12, Taitec, Saitama, Japan) operating at 3,200 rpm. Soluble proteins released from the bacterial cells were collected by centrifugation for 15 min at 20,400 ×g and 4°C.

The rBLG was purified from the prepared lysate using a HisTrap HP column (1 mL, precharged with Ni2+; GE Healthcare) under native conditions. The phosphate buffer-equilibrated column was filled with the prepared lysate and then the flow-through was collected. Next, nonadsorbed proteins were eluted using wash buffer (phosphate buffer containing 20 mM imidazole). Adsorbed proteins were eluted with elution buffers (phosphate buffer containing 31, 63, 125, 250, or 500 mM imidazole). The prepurification crude lysate and the flow-through and eluted fractions were analyzed by Western blotting with an anti-6x His-tag Ab. Eluted fractions were dialyzed against Tris-buffered saline (TBS; 50 mM Tris-HCl (pH 8.0), 138 mM NaCl, and 2.7 mM KCl) and frozen at −80°C until use. The protein concentration of the dialyzed samples was measured with a BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA) before the samples were frozen.

2.5. Trypsin Digestion of BLG

Commercial BLG (cBLG; Sigma) was dissolved in TBS at a concentration of 1 mg/mL. Purified TBS-dialyzed rBLG was diluted to 50 μg/mL with TBS. Trypsin (from porcine pancreas, Wako Pure Chemical Industries Ltd., Osaka, Japan) was added at an enzyme to substrate ratio of 1 : 20 (w/w) and the mixture was incubated at 37°C for 24 h with gentle agitation. Digestion was stopped by heating the sample at 90°C for 5 min. The reaction mixture was kept frozen at −80°C until used in experiments.

2.6. Analysis of DPP-IV Inhibition

The DPP-IV inhibition assay was performed using a DPP-IV Drug Discovery Kit according to the manufacturer’s instructions. Fluorescence resulting from degradation of substrate (H-Gly-Pro-AMC) by DPP-IV was detected using a Fluoroskan Ascent FL Microplate Fluorometer (Thermo Scientific) at excitation and emission wavelengths of 355 and 460 nm, respectively. Data are expressed as DPP-IV activity (%) remaining in test samples versus the control (no sample added).

2.7. cBLG-Immunized Mice

Pathogen-free female BALB/c mice (4 weeks of age, ) were purchased from Japan SLC (Shizuoka, Japan) and housed under temperature- and light-controlled conditions. Mice were fed a standard diet (MF, Oriental Yeast Co., Ltd., Tokyo, Japan) and sterile water ad libitum. After a 1-week preliminary acclimatization period, mice were sensitized with 100 μg of cBLG emulsified with 0.1 mL of complete Freund’s adjuvant (Difco Laboratories, Detroit, MI, USA) and injected intraperitoneally. At 2 and 4 weeks after the first sensitization, mice were boosted with 100 μg of cBLG emulsified with 0.1 mL of incomplete Freund’s adjuvant (Difco Laboratories). All experimental procedures were conducted in accordance with the Regulations for Animal Experimentation of Shinshu University.

2.8. Immunoreactivity Assay

To investigate whether rBLG is immunoreactive, splenocytes were isolated from cBLG-immunized mice and the level of interleukin- (IL-) 13 mRNA expression was measured using real-time quantitative PCR (qPCR) following stimulation with purified rBLG. Splenocytes were prepared using standard methods [15, 16] and then cultured at a final concentration of cells/well (total volume of 2 mL per well). Splenocytes were stimulated with 50 or 100 μg/mL of cBLG or purified rBLG. After 72 h of incubation, cells were harvested and IL-13 mRNA expression was assessed using qPCR as previously described [16]. Fluorescent qPCR was performed with SYBR Premix Ex Taq (TaKaRa Bio Inc., Tokyo, Japan) and IL-13-specific primers, with each reaction containing 5 ng of cDNA in a total volume of 25 μL. The β-actin-specific and IL-13-specific primers were purchased from TaKaRa Bio Inc. The PCR cycling conditions were 10 s at 95°C followed by 45 cycles of 5 s at 95°C and 30 sec at 60°C. As a control, poly RNA samples were used as templates to check for the presence of contaminating genomic DNA. Reaction sensitivity and amplification of contaminant products (e.g., extension of self-annealed primers) were evaluated by amplifying serial dilutions of the cDNA template. For cross-sample comparisons of results obtained using various treatments, cytokine mRNA levels were first normalized to β-actin mRNA levels. Results are presented as the mean and SD of three independent experiments.

2.9. Statistical Analysis

ANOVA and post hoc tests were performed using the ystat2004.xls statistical software package (Igakutosho Shuppan, Tokyo, Japan). One-way ANOVA with the post hoc Dunnett test or Student-Newman-Keuls test was used to determine the significance of differences in DPP-IV inhibitory assay and immunoreactivity assay, respectively. Differences were considered significant at .

3. Results and Discussion

3.1. Construction of the rBLG-Secreting NZ9000 Strain

Genetically engineered LAB have recently emerged as suitable vehicles for the delivery of therapeutic proteins (e.g., antigens of pathogenic bacteria, allergen, and immunomodulators such as cytokines) to the intestinal mucosa [17]. Many heterologous gene expression systems for LAB have been developed [1820]. The nisin-controlled gene expression (NICE) system, which utilizes a nisin-inducible promoter to express downstream genes [21], is one of the most efficient expression systems and is commonly used with L. lactis and other LAB [22, 23].

In the current study, we constructed the secretion plasmid pNZ8148#2:SEC (Figure 1(a)), which is a modified form of pNZ8148, the standard plasmid used in the NICE system. The pNZ8148#2:SEC plasmid contains sequences encoding the nisin-inducible promoter (), usp45 signal peptide (), 6x His-tag, a Factor Xa recognition site, and a terminator. This plasmid was cloned from the unmutated BLG gene (Figure 1(b)) and then introduced into NZ9000, resulting in the generation of NZ9000:SEC-BLG. The NZ9000:SEC-BLG strain was induced with nisin, and rBLG expression and secretion were validated by Western blotting with an anti-6x His-tag Ab. A strong secretory rBLG precursor signal (pre-rBLG, 27 kDa) and a weak band representing the secretory form of rBLG (24.3 kDa) were observed on Western blotting of the cell extract of nisin-induced NZ9000:SEC-BLG (Figure 2(a)). Moreover, a single band corresponding to rBLG was detected in the culture supernatant of nisin-induced NZ9000:SEC-BLG (Figure 2(b)). No signal was detected in analyses of protein extracts of the nisin-induced NZ9000:SEC-VC and noninduced NZ9000 strains (Figure 2). We clearly demonstrated that NZ9000:SEC-BLG intracellular expression of pre-rBLG is dependent on nisin stimulation and that this protein is subsequently secreted by the cell’s secretory machinery [18].

3.2. Optimal Conditions for rBLG Secretion by NZ9000

Previous studies suggested that the amount of a protein expressed in an engineered LAB may be increased in a nisin-concentration-dependent manner using the NICE system [24]. We addressed this possibility in our previous research [13, 14]. In this study, we show that rBLG expression and secretion are nisin-concentration dependent (Figure 3(b)). Inhibition of bacterial proliferation (Figure 3(a)) and an increase in the intensity of a band corresponding to pre-rBLG in the culture supernatant (Figure 3(b)) were observed in NZ9000:SEC-BLG cultured with nisin at concentrations greater than 16 ng/mL.

Nisin, a typical type-A(I) lantibiotic produced by some L. lactis strains, exhibits bactericidal activity against a wide range of Gram-positive bacteria [25]. The mechanism of nisin’s antimicrobial action is thought to involve (i) inhibition of cell wall biosynthesis by scavenging of the peptidoglycan precursor lipid II and (ii) lysis of the cell membrane by the formation of pores [26]. Our observations suggest that although the level of rBLG production by NZ9000:SEC-BLG increases in a nisin-concentration-dependent manner, exposure to high nisin concentrations (i.e., >16 ng/mL) results in significant cell damage. Based on these results, 15 ng/mL was determined to be the optimal nisin concentration for maximizing rBLG secretion.

3.3. Purification of rBLG Produced by NZ9000

Expression of rBLG by strain NZ9000:SEC-BLG was induced in a 4 L large-scale culture, after which the protein was isolated and purified. The cellular crude lysate was passed through a HisTrap HP column and the flow-through was collected. The column was washed to remove nonadsorbed proteins and the adsorbed proteins were eluted with various concentrations of imidazole (20 to 500 mM). To confirm the purification of rBLG, all fractions were analyzed by Western blotting with an anti-6x His-tag Ab (Figure 4). Bands corresponding to pre-rBLG and/or rBLG were observed in each of the eluted fractions. Pre-rBLG and rBLG were particularly abundant in the fractions eluted with 63 and 125 mM imidazole. However, highly purified rBLG samples (i.e., fractions eluted with 250 and 500 mM imidazole) were used in subsequent experiments.

3.4. Inhibition of DPP-IV Activity by Trypsin-Digested rBLG

Trypsin-digested cBLG inhibited the activity of the DPP-IV enzyme in a concentration-dependent manner (Figure 5(a)). The inhibitory activity of trypsin-digested rBLG against DPP-IV was similar to that of cBLG (Figure 5(b)). Uchida et al. also showed that DPP-IV inhibitory activity of trypsin-digested BLG was exerted in a concentration-dependent fashion, and IC50 value was 210 μM [8]. Thus, highly concentrated tryptic hydrolysate of rBLG may efficiently inhibit DPP-IV activity. Other studies have shown that some peptides produced by trypsin digestion of BLG inhibit DPP-IV activity [6, 8]. Particularly, the pentapeptide IPAVF exhibits the strongest inhibitory activity [6]. The strong inhibition of DPP-IV activity observed with trypsin-digested rBLG in this study was probably because of the involvement of these peptides within the rBLG.

3.5. Immunoreactivity of rBLG

Vaccines using genetically modified LAB as mucosal antigen delivery vehicles have been tested in mouse models of allergies to house dust mites [2729], eggs [30], birch pollen [31], Japanese cedar pollen [32], and cow’s milk [33]. These studies demonstrated suppression of the allergic response by LAB vaccines through induction of immune response by T-helper (Th)1 or regulatory T cells. Indeed, Adel-Patient et al. showed that oral pretreatment with a BLG-producing L. lactis strain prevents Th2-type immune responses through a reduction in BLG-specific IgE production and the upregulation of specific Th1-type IgG2a and fecal IgA production [34]. Therefore, we also investigated the immunoreactivity of L. lactis-produced rBLG using a simple in vitro assay system that we previously developed [13, 14]. In this study, IL-13 mRNA expression was significantly enhanced in a dose-dependent manner in splenocytes stimulated with cBLG as compared with medium-stimulated control cells (Supplemental Figure 1 available online at Similar results were observed with cells stimulated with purified rBLG (Supplemental Figure 1). These results indicate that rBLG demonstrates immunoreactivity as strong as that of cBLG. Hence, NZ9000:SEC-BLG may be useful not only in managing T2D but also in therapies to treat or prevent allergies to cow’s milk.

4. Conclusions

We developed a L. lactis strain (NZ9000 : SEC-BLG) that efficiently secretes rBLG. The rBLG produced by this strain demonstrates both strong allergenicity and inhibition of DPP-IV activity following trypsin digestion. The NZ9000:SEC-BLG strain may prove useful in therapies for treating T2D and allergies to cow’s milk.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


The authors thank Mr. Jiro Maeda (Faculty of Agriculture, Shinshu University) for excellent animal care and technical support. The study was supported by a grant from the Iijima Memorial Foundation for the Promotion of Food Science and Technology to Takeshi Shimosato.

Supplementary Materials

Supplemental Figure 1: Immunoreactivity of rBLG. Splenocytes isolated from cBLG-sensi1zed BALB/c mice were stimulated in medium with or without (Med; white bar) 50 or 100 μg/mL of cBLG (cBLG; dotted-white bar) or purified rBLG (rBLG; dotted-black bar). After 72 h, IL-13 mRNA levels were measured using real-time qPCR. Values represent means and error bars indicate SD (n=3). Items indicate with different letters (i.e. a, b, c, and d) were significantly different (p<0.01). Similar results were obtained from three different mice

  1. Supplementary Material


  1. B. Hernández-Ledesma, I. Recio, and L. Amigo, “β-Lactoglobulin as source of bioactive peptides,” Amino Acids, vol. 35, no. 2, pp. 257–265, 2008. View at: Publisher Site | Google Scholar
  2. D. E. W. Chatterton, G. Smithers, P. Roupas, and A. Brodkorb, “Bioactivity of β-lactoglobulin and α-lactalbumin—technological implications for processing,” International Dairy Journal, vol. 16, no. 11, pp. 1229–1240, 2006. View at: Publisher Site | Google Scholar
  3. I. M. E. Lacroix and E. C. Y. Li-Chan, “Inhibition of dipeptidyl peptidase (DPP)-IV and α-glucosidase activities by pepsin-treated whey proteins,” Journal of Agricultural and Food Chemistry, vol. 61, no. 31, pp. 7500–7506, 2013. View at: Publisher Site | Google Scholar
  4. I. M. Lacroix and E. C. Li-Chan, “Isolation and characterization of peptides with dipeptidyl peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins,” Peptides, vol. 54, pp. 39–48, 2014. View at: Google Scholar
  5. A. B. Nongonierma and R. J. Fitzgerald, “Dipeptidyl peptidase IV inhibitory and antioxidative properties of milk protein-derived dipeptides and hydrolysates,” Peptides, vol. 39, no. 1, pp. 157–163, 2013. View at: Publisher Site | Google Scholar
  6. S. T. Silveira, D. Martínez-Maqueda, I. Recio, and B. Hernández-Ledesma, “Dipeptidyl peptidase-IV inhibitory peptides generated by tryptic hydrolysis of a whey protein concentrate rich in β-lactoglobulin,” Food Chemistry, vol. 141, no. 2, pp. 1072–1077, 2013. View at: Publisher Site | Google Scholar
  7. G. Tulipano, V. Sibilia, A. M. Caroli, and D. Cocchi, “Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors,” Peptides, vol. 32, no. 4, pp. 835–838, 2011. View at: Publisher Site | Google Scholar
  8. M. Uchida, Y. Ohshiba, and O. Mogami, “Novel dipeptidyl peptidase-4-inhibiting peptide derived from β-lactoglobulin,” Journal of Pharmacological Sciences, vol. 117, no. 1, pp. 63–66, 2011. View at: Publisher Site | Google Scholar
  9. R. Thoma, B. Löffler, M. Stihle, W. Huber, A. Ruf, and M. Hennig, “Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV,” Structure, vol. 11, no. 8, pp. 947–959, 2003. View at: Publisher Site | Google Scholar
  10. G. E. Lim and P. L. Brubaker, “Glucagon-like peptide 1 secretion by the L-cell: the view from within,” Diabetes, vol. 55, no. 2, pp. S70–S77, 2006. View at: Publisher Site | Google Scholar
  11. L. K. Phillips and J. B. Prins, “Update on incretin hormones,” Annals of the New York Academy of Sciences, vol. 1243, pp. E55–E74, 2011. View at: Publisher Site | Google Scholar
  12. C. Daniel, Y. Roussel, M. Kleerebezem, and B. Pot, “Recombinant lactic acid bacteria as mucosal biotherapeutic agents,” Trends in Biotechnology, vol. 29, no. 10, pp. 499–508, 2011. View at: Publisher Site | Google Scholar
  13. S. Shigemori, S. Yonekura, T. Sato, M. Nakanishi, H. Otani, and T. Shimosato, “Expression of a biologically active GFP-αS1-casein fusion protein in Lactococcus lactis,” Current Microbiology, vol. 64, no. 6, pp. 569–575, 2012. View at: Publisher Site | Google Scholar
  14. S. Shigemori, S. Yonekura, T. Sato, H. Otani, and T. Shimosato, “Expression of the immunoreactive buckwheat major allergenic storage protein in Lactococcus lactis,” Applied Microbiology and Biotechnology, vol. 97, no. 8, pp. 3603–3611, 2013. View at: Publisher Site | Google Scholar
  15. Y. Ito, S. Shigemori, T. Sato et al., “Class I/II hybrid inhibitory oligodeoxynucleotide exerts Th1 and Th2 double immunosuppression,” FEBS Open Bio, vol. 3, pp. 41–45, 2013. View at: Publisher Site | Google Scholar
  16. T. Shimosato, M. Tohno, T. Sato et al., “Identification of a potent immunostimulatory oligodeoxynucleotide from Streptococcus thermophilus lacZ,” Animal Science Journal, vol. 80, no. 5, pp. 597–604, 2009. View at: Publisher Site | Google Scholar
  17. J. M. Wells and A. Mercenier, “Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria,” Nature Reviews Microbiology, vol. 6, no. 5, pp. 349–362, 2008. View at: Publisher Site | Google Scholar
  18. E. Morello, L. G. Bermúdez-Humarán, D. Llull et al., “Lactococcus lactis, an efficient cell factory for recombinant protein production and secretion,” Journal of Molecular Microbiology and Biotechnology, vol. 14, no. 1–3, pp. 48–58, 2007. View at: Publisher Site | Google Scholar
  19. M. Bahey-El-Din, C. G. M. Gahan, and B. T. Griffin, “Lactococcus lactis as a cell factory for delivery of therapeutic proteins,” Current Gene Therapy, vol. 10, no. 1, pp. 34–45, 2010. View at: Publisher Site | Google Scholar
  20. D. S. Pontes, M. S. P. de Azevedo, J. M. Chatel, P. Langella, V. Azevedo, and A. Miyoshi, “Lactococcus lactis as a live vector: heterologous protein production and DNA delivery systems,” Protein Expression and Purification, vol. 79, no. 2, pp. 165–175, 2011. View at: Publisher Site | Google Scholar
  21. P. G. de Ruyter, O. P. Kuipers, and W. M. de Vos, “Controlled gene expression systems for Lactococcus lactis with the food- grade inducer nisin,” Applied and Environmental Microbiology, vol. 62, no. 10, pp. 3662–3667, 1996. View at: Google Scholar
  22. I. Mierau and M. Kleerebezem, “10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis,” Applied Microbiology and Biotechnology, vol. 68, no. 6, pp. 705–717, 2005. View at: Publisher Site | Google Scholar
  23. X. X. Zhou, W. F. Li, G. X. Ma, and Y. J. Pan, “The nisin-controlled gene expression system: construction, application and improvements,” Biotechnology Advances, vol. 24, no. 3, pp. 285–295, 2006. View at: Publisher Site | Google Scholar
  24. L. G. Bermúdez-Humarán, P. Kharrat, J. Chatel, and P. Langella, “Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines,” Microbial Cell Factories, vol. 10, supplement 1, article S4, 2011. View at: Publisher Site | Google Scholar
  25. E. Gross and J. L. Morell, “The structure of nisin,” Journal of the American Chemical Society, vol. 93, no. 18, pp. 4634–4635, 1971. View at: Publisher Site | Google Scholar
  26. M. R. Islam, J. Nagao, T. Zendo, and K. Sonomoto, “Antimicrobial mechanism of lantibiotics,” Biochemical Society Transactions, vol. 40, no. 6, pp. 1528–1533, 2012. View at: Publisher Site | Google Scholar
  27. Y. Charng, C. Lin, and C. Hsu, “Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic-acid bacteria,” Vaccine, vol. 24, no. 33-34, pp. 5931–5936, 2006. View at: Publisher Site | Google Scholar
  28. A. Kruisselbrink, M. H. Den Bak-Glashouwer, C. E. G. Havenith, J. E. R. Thole, and R. Janssen, “Recombinant Lactobacillus plantarum inhibits house dust mite-specific T-cell responses,” Clinical and Experimental Immunology, vol. 126, no. 1, pp. 2–8, 2001. View at: Publisher Site | Google Scholar
  29. P. Rigaux, C. Daniel, M. Hisbergues et al., “Immunomodulatory properties of Lactobacillus plantarum and its use as a recombinant vaccine against mite allergy,” Allergy, vol. 64, no. 3, pp. 406–414, 2009. View at: Publisher Site | Google Scholar
  30. I. L. Huibregtse, V. Snoeck, A. de Creus et al., “Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin,” Gastroenterology, vol. 133, no. 2, pp. 517–528, 2007. View at: Publisher Site | Google Scholar
  31. C. Daniel, A. Repa, C. Wild et al., “Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1,” Allergy, vol. 61, no. 7, pp. 812–819, 2006. View at: Publisher Site | Google Scholar
  32. K. Ohkouchi, S. Kawamoto, K. Tatsugawa et al., “Prophylactic effect of Lactobacillus oral vaccine expressing a Japanese cedar pollen allergen,” Journal of Bioscience and Bioengineering, vol. 113, no. 4, pp. 536–541, 2012. View at: Publisher Site | Google Scholar
  33. M. S. P. de Azevedo, S. Innocentin, F. A. Dorella et al., “Immunotherapy of allergic diseases using probiotics or recombinant probiotics,” Journal of Applied Microbiology, vol. 115, no. 2, pp. 319–333, 2013. View at: Publisher Site | Google Scholar
  34. K. Adel-Patient, S. Ah-Leung, C. Creminon et al., “Oral administration of recombinant Lactococcus lactis expressing bovine β-lactoglobulin partially prevents mice from sensitization,” Clinical and Experimental Allergy, vol. 35, no. 4, pp. 539–546, 2005. View at: Publisher Site | Google Scholar

Copyright © 2014 Suguru Shigemori et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.